摘要
目的:探讨参一胶囊联合吉西他滨注射液治疗晚期野生型老年肺腺癌的临床疗效。方法:对中山市中医医院肿瘤科2019年5月1日-2019年11月30日36例晚期野生型老年肺腺癌患者进行用药比对研究。其中,中西医联合组(予参一胶囊联合吉西他滨注射液治疗)19例,单纯西医组(单用吉西他滨注射液)17例。结果:两组在提高患者生活质量方面的差异具有统计学意义(P<0.05)。治疗后,两组组内及组间瘤体大小的差异具有统计学意义(P<0.05)。治疗后,两组患者免疫指标CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)的差异有统计学意义(P<0.05)。治疗后中西医结合组CD3^(+)、CD4^(+)水平较治疗前升高,与西医组的差异具有统计学意义(P<0.05)。治疗后,西医组CD8^(+)水平较治疗前升高(P<0.05),中西医结合组CD8^(+)水平与治疗前相比降低,差异有统计学意义(P<0.05)。两组在常见不良反应(骨髓抑制、恶心呕吐、脱发)发生率方面未见明显差异(P>0.05)。结论:与单纯吉西他滨化疗相比,参一胶囊联合单药吉西他滨化疗在稳定晚期老年野生型肺腺癌患者的瘤体大小、提高生活质量方面有明显优势,且体现出一定的免疫调节能力,临床疗效较好,未见明显的不良反应。
Objective:To investigate the clinical efficacy of the Shenyi capsules plus(参一胶囊)gemcitabine injection on advanced wild-type elderly lung adenocarcinoma.Methods:A comparative study was performed on 36 cases from May 1,2019 to November 30,2019.Among them,there were 19 cases in the combined medicine group(took the Shenyi capsules plus gemcitabine injection),and 17 cases in the Western medicine group(received single gemcitabine injection).Results:The difference between the two groups in improving the quality of life was statistically significant(P<0.05).After treatment,the differences between the two groups and within each group in tumor size were statistically significant(P<0.05).After treatment,the differences of immune indexes CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)between the two groups were statistically significant(P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in the integrated medicine group were higher than those before treatment,and there was a statistically significant difference between the two groups(P<0.05).After treatment,the level of CD8^(+)in the Western medicine group was higher than that before treatment(P<0.05),and in the integrated medicine group was lower than that before treatment,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of common adverse reactions(myelosuppression,nausea and vomiting,and alopecia)between the two groups(P>0.05).Conclusion:Compared with simple gemcitabine chemotherapy,the Shenyi capsules plus single gemcitabine chemotherapy has obvious advantages in stabilizing the tumor size and improving the quality of life of the advanced wild-type lung adenocarcinoma patient,and it shows a certain immune regulation ability.The curative effect is good,and no obvious adverse reaction is found.
作者
李陆振
陈婷
方灿途
伍家鸣
LI Luzhen;Chen Ting;Fang Cantu;Wu Jiaming
出处
《中医临床研究》
2022年第21期134-137,共4页
Clinical Journal Of Chinese Medicine
关键词
晚期肺腺癌
参一胶囊
化疗
老年
Advanced lung adenocarcinoma
The Shenyi capsule
Gemcitabine
Chemotherapy
Old age
